Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Allergy and Immunology

Taking Control: The Stepwise Treatment Plan

At a Glance

The standard treatment for chronic urticaria follows a 4-step guideline aiming for zero hives and zero itch. It starts with daily non-sedating antihistamines, progresses to physician-supervised dose increases (up to 4x), adds biologics like Omalizumab, and finally considers Cyclosporine.

Managing chronic hives is no longer a matter of “waiting for it to go away.” Modern international guidelines (EAACI/GA²LEN) provide a clear, four-step roadmap with one goal in mind: complete control (zero hives and zero itch) [1][2]. If your symptoms are not fully controlled, it is likely time to discuss moving to the next step with your specialist. This algorithm generally applies to both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU) [2].

The 4-Step Treatment Roadmap

The following steps are designed to be followed sequentially, typically waiting 2 to 4 weeks between steps to evaluate effectiveness [2].

Step 1: Standard Antihistamines

The foundation of treatment is a daily, non-sedating, second-generation H1-antihistamine (such as cetirizine, loratadine, or fexofenadine) [2][3]. These are safer and more effective for chronic use than older, “drowsy” antihistamines like diphenhydramine [4].

Step 2: Updosing (Up to 4x)

If a standard dose doesn’t provide relief, the next step is to increase the dose of that same antihistamine. Guidelines allow for up to four times the standard daily dose [2][5]. Research shows that many patients who don’t respond to one pill find relief at these higher doses [6].

CRITICAL WARNING: Do not do this on your own. You should never increase your medication dose without direct instruction and supervision from your doctor. While usually well-tolerated, updosing can cause significant drowsiness (somnolence) in some people, creating a safety hazard. Use caution when driving or operating machinery until you know how the higher dose affects you [7].

Step 3: Omalizumab (Anti-IgE)

For those who still have hives despite high-dose antihistamines, Omalizumab (a biologic medication) is added [8].

  • How it works: It is a humanized antibody that binds to circulating IgE (the “allergy” antibody) [9]. By “mopping up” these antibodies, it prevents them from latching onto your mast cells and triggering a histamine release [10][11].
  • Success & Safety: It has a very favorable safety profile and often provides rapid, dramatic improvement [12][13]. Note: While generally safe, there is a rare FDA black box warning for an allergic reaction (anaphylaxis) to the injection itself, which is why patients are monitored in the clinic for a period of time after their first few doses [12].

Step 4: Cyclosporine

If symptoms remain refractory (stubborn) after Step 3, Cyclosporine A may be added [14]. This medication calms the immune system more broadly. While highly effective, it requires more frequent monitoring for side effects like blood pressure or kidney changes [15].

The Steroid Warning

A major “red flag” in chronic urticaria management is the long-term use of systemic corticosteroids (like prednisone).

  • Short-term only: Steroids should only be used for a few days to get a severe flare under control [16].
  • The Risk: They are not recommended for long-term use because they do not fix the underlying cause and carry a high risk of significant side effects, such as weight gain, bone loss, and mood changes [17][16].

Pregnancy and Breastfeeding

Because chronic hives frequently affect women of childbearing age, it is important to discuss family planning with your doctor. Many standard treatments, including certain antihistamines and biologics, have specific guidelines for use during pregnancy and breastfeeding, which your doctor can help you navigate.

Hope for the Future: Emerging Therapies

If current treatments fail, new “biological keys” are becoming available through clinical trials and recent approvals [18].

  • Remibrutinib: A “BTK inhibitor” that blocks the internal signaling within mast cells. It has shown fast and sustained improvement in symptoms for patients who fail antihistamines [19][20].
  • Dupilumab: Originally used for asthma and eczema, this medication targets different immune pathways (IL-4 and IL-13) and is showing promise for certain types of chronic hives [21][22].

To understand how to track your progress through these steps, visit Tracking Your Path to Control.

Common questions in this guide

Can I take more than the standard dose of antihistamines for my chronic hives?
Yes, international treatment guidelines allow doctors to increase standard non-sedating antihistamines up to four times the normal daily dose. However, you must never increase your medication without direct instruction and supervision from your healthcare provider.
What is the next step if high-dose antihistamines do not stop my hives?
If high-dose antihistamines fail to control your symptoms, the next recommended step is typically a biologic medication called Omalizumab. This injected therapy binds to the allergy antibodies in your blood to stop them from triggering hive-causing histamine release.
Are oral steroids a good long-term treatment for chronic urticaria?
No. While short courses of oral steroids like prednisone can help calm a severe flare-up, they are strongly discouraged for long-term use. Chronic steroid use carries high risks for serious side effects like bone loss, weight gain, and mood changes.
What new treatments are available for stubborn chronic hives?
For hives that do not respond to standard antihistamines or Omalizumab, newer therapies are emerging through clinical trials. These include Remibrutinib, which blocks internal mast cell signals, and Dupilumab, a biologic that targets different immune pathways.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my current treatment plan aligned with the EAACI/GA²LEN international guidelines?
  2. 2.If the standard dose of antihistamines isn't working, can we safely try updosing (up to 4x) before moving to more advanced therapies?
  3. 3.Am I a candidate for Omalizumab, and how long does it typically take to see 'complete control' after starting?
  4. 4.Are there risks to using prednisone for more than a few days at a time for my flares?
  5. 5.Would I be eligible for newer treatments like Remibrutinib or Dupilumab if standard biologics don't work?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.

    Maurer M, Zuberbier T, Metz M

    Handbook of experimental pharmacology 2022; (268()):117-133 doi:10.1007/164_2021_506.

    PMID: 34247278
  2. 2

    Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.

    Ari A, Levy Y, Segal N, et al.

    Pediatric dermatology 2020; (37(6)):1051-1054 doi:10.1111/pde.14360.

    PMID: 32951239
  3. 3

    A Retrospective Cohort Study on the Comorbidity in 19,264 Chinese Patients of Different Ages with Urticaria.

    Xiao M, Zhang X, Guo A, et al.

    Acta dermato-venereologica 2024; (104()):adv24050 doi:10.2340/actadv.v104.24050.

    PMID: 38932592
  4. 4

    Evaluating and managing chronic idiopathic urticaria in adults.

    Webster L, Rider NL, Archambault ME

    JAAPA : official journal of the American Academy of Physician Assistants 2018; (31(7)):22-26 doi:10.1097/01.JAA.0000534976.46365.11.

    PMID: 29889715
  5. 5

    Basophil CD63 expression in chronic spontaneous urticaria: correlation with allergic sensitization, serum autoreactivity and basophil reactivity.

    Chen Q, Zhai Z, Xu J, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(3)):463-468 doi:10.1111/jdv.13912.

    PMID: 27518369
  6. 6

    Efficacy and Safety of Up-dosed Second-generation Antihistamines in Uncontrolled Chronic Spontaneous Urticaria: A Review.

    Podder I, Dhabal A, Chakraborty SS

    The Journal of clinical and aesthetic dermatology 2023; (16(3)):44-50.

    PMID: 36950042
  7. 7

    Pathobiology of Second-Generation Antihistamines Related to Sleep in Urticaria Patients.

    Mann C, Wegner J, Weeß HG, Staubach P

    Biology 2022; (11(3)) doi:10.3390/biology11030433.

    PMID: 35336805
  8. 8

    New treatments for chronic urticaria.

    Kolkhir P, Altrichter S, Munoz M, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2020; (124(1)):2-12 doi:10.1016/j.anai.2019.08.014.

    PMID: 31446134
  9. 9

    A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.

    Russo F, Cortonesi G, Lazzeri L, et al.

    Dermatologic therapy 2022; (35(11)):e15859 doi:10.1111/dth.15859.

    PMID: 36164841
  10. 10

    A review of omalizumab for the management of severe asthma.

    Lin CH, Cheng SL

    Drug design, development and therapy 2016; (10()):2369-78 doi:10.2147/DDDT.S112208.

    PMID: 27528798
  11. 11

    Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.

    Metz M, Staubach P, Bauer A, et al.

    Theranostics 2017; (7(5)):1266-1276 doi:10.7150/thno.18304.

    PMID: 28435464
  12. 12

    Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.

    Chu AWL, Oykhman P, Chu X, et al.

    The Journal of allergy and clinical immunology 2025; (156(4)):1008-1023 doi:10.1016/j.jaci.2025.06.004.

    PMID: 40663028
  13. 13

    Effective treatment with omalizumab of a patient with spontaneous chronic urticaria and eosinophilic esophagitis.

    Provenzano E, Morrone P

    The Journal of dermatological treatment 2018; (29(sup4)):5-7 doi:10.1080/09546634.2018.1527992.

    PMID: 30265608
  14. 14

    Chronic Spontaneous Urticaria: A Review.

    Kolkhir P, Bonnekoh H, Metz M, Maurer M

    JAMA 2024; (332(17)):1464-1477 doi:10.1001/jama.2024.15568.

    PMID: 39325444
  15. 15

    [Diagnostic and Therapeutic Approach of Chronic Spontaneous Urticaria: Recommendations in Portugal].

    Costa C, Gonçalo M,

    Acta medica portuguesa 2016; (29(11)):763-781 doi:10.20344/amp.8294.

    PMID: 28229846
  16. 16

    Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

    Chu X, Wang J, Ologundudu L, et al.

    The journal of allergy and clinical immunology. In practice 2024; (12(7)):1879-1889.e8 doi:10.1016/j.jaip.2024.04.016.

    PMID: 38642709
  17. 17

    The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

    Zuberbier T, Ansari ZA, Abdul Latiff AH, et al.

    Allergy 2026; (81(8)):2582-2632 doi:10.1111/all.70210.

    PMID: 41649409
  18. 18

    Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

    Roskoski R

    Pharmacological research 2026; (227()):108187 doi:10.1016/j.phrs.2026.108187.

    PMID: 41937093
  19. 19

    Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks.

    Hayama K, Chinuki Y, Yagami A, et al.

    Dermatology and therapy 2026; (16(3)):1707-1721 doi:10.1007/s13555-026-01666-5.

    PMID: 41712058
  20. 20

    Remibrutinib in Chronic Spontaneous Urticaria.

    Metz M, Giménez-Arnau A, Hide M, et al.

    The New England journal of medicine 2025; (392(10)):984-994 doi:10.1056/NEJMoa2408792.

    PMID: 40043237
  21. 21

    [Treatment of mast cell-mediated angioedema].

    Smola A, Lochbaum R

    Dermatologie (Heidelberg, Germany) 2026; doi:10.1007/s00105-026-05753-8.

    PMID: 42489912
  22. 22

    Comparative efficacy of omalizumab, dupilumab, and remibrutinib in chronic spontaneous urticaria: a network meta-analysis of randomized control trials.

    Xiong G, Rayner DG, Kim L, et al.

    The Journal of dermatological treatment 2025; (36(1)):2580374 doi:10.1080/09546634.2025.2580374.

    PMID: 41186128

This page explains standard treatment guidelines for chronic urticaria for educational purposes only. It does not replace professional medical advice, and you should never change your medication doses without consulting your doctor.

Get notified when new evidence is published on chronic urticaria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.